ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-32.1 - CERTIFICATION - November 29, 2017

Attached files

file filename
EX-10.14 - FORM OF RESTRICTED STOCK UNIT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT BETWEEN - ORAMED PHARMACEUTICALS INC.f10k2017ex10-14_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2017_oramedpharma.htm
EX-32.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex32-2_oramed.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex31-2_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2017ex31-1_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2017ex23-1_oramed.htm
EX-10.23 - REPRESENTATIVE FORM OF INDEMNIFICATION AGREEMENTS BETWEEN ORAMED PHARMACEUTICALS - ORAMED PHARMACEUTICALS INC.f10k2017ex10-23_oramed.htm
EX-10.11 - AMENDMENT, DATED JUNE 30, 2017, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED L - ORAMED PHARMACEUTICALS INC.f10k2017ex10-11_oramed.htm
EX-3.1 - COMPOSITE COPY OF CERTIFICATE OF INCORPORATION, AS AMENDED AS OF JANUARY 22, 201 - ORAMED PHARMACEUTICALS INC.f10k2017ex3-1_oramed.htm

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Nadav Kidron, President, Chief Executive Officer and a Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 29, 2017 /s/ Nadav Kidron
 

Nadav Kidron

President and Chief Executive Officer

     

 

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports